Springer Medicine
@springermedicine.com
Trustworthy, tailored, cutting-edge content for medical professionals who want to deliver the best possible care. Learn more here: springermedicine.com
Screening, diet, and lifestyle are the three pillars of prevention for #CRC, but how can the latest research, including that on behavioral interventions, be leveraged?
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
November 24, 2025 at 5:16 PM
Screening, diet, and lifestyle are the three pillars of prevention for #CRC, but how can the latest research, including that on behavioral interventions, be leveraged?
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
Our experts discuss in our free-to-access webinar 👉 buff.ly/LVvO2cE
#OncSky #GastroSky
25 years since the first phase 2 trial for the first #TKI, we reflect on this key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
November 21, 2025 at 7:25 PM
25 years since the first phase 2 trial for the first #TKI, we reflect on this key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Listen now 🔉 buff.ly/afBarZg
#OncTwitter
Prof. Edoardo Savarino takes us through the highlights of the updated #UEG and #ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
November 19, 2025 at 3:00 PM
Prof. Edoardo Savarino takes us through the highlights of the updated #UEG and #ESNM #dysphagia guidelines and the difference they could make to patient outcomes.
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
Listen now 🔉 buff.ly/CfJ9oay
#GastroSky
❗ LAST CHANCE TO REGISTER❗
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
November 17, 2025 at 9:01 AM
❗ LAST CHANCE TO REGISTER❗
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar.
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
November 11, 2025 at 4:15 PM
With #AASLD2025 coming to a close, continue your learning on #ALD with our upcoming free webinar.
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
Find out more about advances in treatment and what you need to know about the introduction of #MetALD as a new category of liver disease.
👉 buff.ly/XbXhwMi
#HepSky #MedSky
From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
November 8, 2025 at 1:01 PM
From #ESMO2025 - Prof. Christof Vulsteke shares study findings that position perioperative enfortumab vedotin plus #pembrolizumab as a new option for cisplatin-ineligible muscle-invasive #BladderCancer.
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Watch the full interview 👉 buff.ly/RNdTu6h
#OncSky #MedNews
Refresh your knowledge in #oncology & #hematology:
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
November 5, 2025 at 11:54 AM
Refresh your knowledge in #oncology & #hematology:
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
▪️ 45 clinical cases across different topics with relevant clinical images
▪️ Written by renowned experts
▪️ Knowledge-check questions with answers
Access the cases for free 👉 buff.ly/a8G1qXU
#MedEd #OncSky
From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
November 3, 2025 at 11:54 AM
From #ESMO2025 - Dr. Erica Mayer highlights the benefit of treatment with #giredestrant plus #everolimus in patients with ER-positive, HER2-negative advanced #BreastCancer who have previously received a CDK4/6 inhibitor.
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
Watch now 👉 buff.ly/D0apqEh
#MedNews #OncSky
From #ESMO2025 - Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with #ColonCancer despite the trial not meeting its primary endpoint.
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
October 31, 2025 at 9:02 AM
From #ESMO2025 - Prof. Jeanne Tie explains why ctDNA-guided treatment de-escalation could be considered in certain patients with #ColonCancer despite the trial not meeting its primary endpoint.
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
Watch the full interview 👉 buff.ly/EZ6gTh6
#OncSky #MedNews
From #UEGWeek 2025 - Yorick van de Pavert highlights the benefits of endoscopic #gastroenterostomy vs surgical for patients with malignant gastric outlet obstruction in findings from the ENDURO trial.
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
October 28, 2025 at 10:02 AM
From #UEGWeek 2025 - Yorick van de Pavert highlights the benefits of endoscopic #gastroenterostomy vs surgical for patients with malignant gastric outlet obstruction in findings from the ENDURO trial.
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
Watch the full interview 👉 buff.ly/Vwlo9CV
#GastricCancer
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
October 28, 2025 at 10:02 AM
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Get the latest insights into patient risk and identification, treatment and management, and the arrival of #MetALD.
Register now 👉 buff.ly/zHkugyV
#HepSky #MedSky
Catch up on the top stories and latest innovations in #oncology from #ESMO2025 with our hub page.
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
October 22, 2025 at 10:54 AM
Catch up on the top stories and latest innovations in #oncology from #ESMO2025 with our hub page.
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Access the hub for free here 👉 buff.ly/1l8hWTi
#OncSky #MedNews
Attending #ESMO2025?
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
October 19, 2025 at 10:00 AM
Attending #ESMO2025?
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Head on over to our booth at 2052 to discover more about our #MedEd platform.
Not here in person? Learn more about us here 👉 buff.ly/5tf6S64
#OncSky #MedSky
❗ LAST CHANCE TO REGISTER❗
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
October 17, 2025 at 8:45 AM
❗ LAST CHANCE TO REGISTER❗
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
How can you best treat #FND?
Join our expert-led webinar to increase your confidence in recognizing FND, communicating the diagnosis effectively, and helping your patients manage the disorder.
👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
We will be at #ESMO2025!
Stop by our booth at 2052 and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Stop by our booth at 2052 and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#OncSky #MedSky
October 16, 2025 at 9:30 AM
We will be at #ESMO2025!
Stop by our booth at 2052 and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#OncSky #MedSky
Stop by our booth at 2052 and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#OncSky #MedSky
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Join our expert-led webinar to gain the latest insights into patient risk and identification, treatment, management, and the arrival of #MetALD.
👉 buff.ly/bF2uOeh
#GastroSky #MedEd
Join our expert-led webinar to gain the latest insights into patient risk and identification, treatment, management, and the arrival of #MetALD.
👉 buff.ly/bF2uOeh
#GastroSky #MedEd
October 13, 2025 at 10:54 AM
The global burden of #ALD is growing and compounded by frequent late-stage diagnosis and undertreatment.
Join our expert-led webinar to gain the latest insights into patient risk and identification, treatment, management, and the arrival of #MetALD.
👉 buff.ly/bF2uOeh
#GastroSky #MedEd
Join our expert-led webinar to gain the latest insights into patient risk and identification, treatment, management, and the arrival of #MetALD.
👉 buff.ly/bF2uOeh
#GastroSky #MedEd
Missed #UEGWeek 2025?
Find out the key highlights and top stories with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
Find out the key highlights and top stories with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
October 11, 2025 at 11:02 AM
Missed #UEGWeek 2025?
Find out the key highlights and top stories with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
Find out the key highlights and top stories with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
#FND perplexes and frustrates patients and physicians alike.
Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood.
How can you recognize FND and what are the treatment options? 👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood.
How can you recognize FND and what are the treatment options? 👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
October 8, 2025 at 3:15 PM
#FND perplexes and frustrates patients and physicians alike.
Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood.
How can you recognize FND and what are the treatment options? 👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
Limited knowledge and insufficient awareness delays diagnosis and treatment, and many patients feel misunderstood.
How can you recognize FND and what are the treatment options? 👉 buff.ly/bF2uOeh
#NeuroSky #MedEd
Catch up on the key highlights and top stories from #UEGWeek 2025 with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
October 8, 2025 at 9:30 AM
Catch up on the key highlights and top stories from #UEGWeek 2025 with our hub page.
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
Access the hub for free here 👉 buff.ly/rGbR5dB
#GastroSky #MedNews
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/75J652i
#DiabetesSky #MedSky
Watch now 👉 buff.ly/75J652i
#DiabetesSky #MedSky
October 6, 2025 at 10:54 AM
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/75J652i
#DiabetesSky #MedSky
Watch now 👉 buff.ly/75J652i
#DiabetesSky #MedSky
At #UEGWeek 2025?
Come on over to our booth at 2.16 to learn more about our #MedEd platform.
Not there in person? Learn more about Springer Medicine here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
Come on over to our booth at 2.16 to learn more about our #MedEd platform.
Not there in person? Learn more about Springer Medicine here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
October 5, 2025 at 10:54 AM
At #UEGWeek 2025?
Come on over to our booth at 2.16 to learn more about our #MedEd platform.
Not there in person? Learn more about Springer Medicine here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
Come on over to our booth at 2.16 to learn more about our #MedEd platform.
Not there in person? Learn more about Springer Medicine here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
From #ESCCongress2025 - Prof. Christi Deaton explains why the ESC consensus statement on #MentalHealth and #CVD is needed and outlines the key recommendations.
Watch the full interview here 👉 buff.ly/vZQrLyq
#CardioSky
Watch the full interview here 👉 buff.ly/vZQrLyq
#CardioSky
October 3, 2025 at 10:54 AM
From #ESCCongress2025 - Prof. Christi Deaton explains why the ESC consensus statement on #MentalHealth and #CVD is needed and outlines the key recommendations.
Watch the full interview here 👉 buff.ly/vZQrLyq
#CardioSky
Watch the full interview here 👉 buff.ly/vZQrLyq
#CardioSky
Heading to #UEGWeek 2025?
Stop by our booth and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
Stop by our booth and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
October 3, 2025 at 9:30 AM
Heading to #UEGWeek 2025?
Stop by our booth and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
Stop by our booth and discover how we can support your medical education.
Not attending in person? Learn more about our #MedEd platform here 👉 buff.ly/5tf6S64
#GastroSky #MedSky
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/sxRkwHW
#MedSky #DiabetesSky
Watch now 👉 buff.ly/sxRkwHW
#MedSky #DiabetesSky
October 2, 2025 at 8:15 AM
From #EASD2025 - Profs Jane Speight & Richard Holt discuss the importance of the launch of the first draft of the EASD clinical practice guideline on the assessment & management of distress in adults with type 1 or type 2 #diabetes.
Watch now 👉 buff.ly/sxRkwHW
#MedSky #DiabetesSky
Watch now 👉 buff.ly/sxRkwHW
#MedSky #DiabetesSky
What are the best treatment options for your patients with #FND?
Prof. Mark Edwards discusses this and more, in our upcoming live webinar.
Register for free 👉 buff.ly/kpovihk
#NeuroSky #NeuroMed #MedEd
Prof. Mark Edwards discusses this and more, in our upcoming live webinar.
Register for free 👉 buff.ly/kpovihk
#NeuroSky #NeuroMed #MedEd
October 1, 2025 at 10:54 AM
What are the best treatment options for your patients with #FND?
Prof. Mark Edwards discusses this and more, in our upcoming live webinar.
Register for free 👉 buff.ly/kpovihk
#NeuroSky #NeuroMed #MedEd
Prof. Mark Edwards discusses this and more, in our upcoming live webinar.
Register for free 👉 buff.ly/kpovihk
#NeuroSky #NeuroMed #MedEd